Mar 02,2023

Closing the Cancer Gap: The Multicancer Early Detection (MCED) Consortium Releases Two New Health Equity Papers

The Multicancer Early Detection (MCED) Consortium, a public-private collaboration between organizations in the U.S. and the U.K., is dedicated to reducing the burden of cancer by evaluating how MCED technologies may improve cancer detection, treatment, and care to benefit all people. The papers examine the benefits, harms, and modifiable barriers to the acceptability and uptake of MCEDs among diverse, underrepresented populations and offer insightful recommendations to support equitable and informed participation in these emerging technologies. These documents serve as a key step in determining how MCED technologies could be used to reduce longstanding disparities in cancer care.

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

FREENOME PRESENTS A SUBJECT POPULATION ANALYSIS OF A CLINICAL STUDY USING A MULTIOMICS BLOOD TEST FOR THE EARLY DETECTION OF COLORECTAL CANCER

Today Freenome, a privately held biotech company, presents a subject population analysis from PREEMPT CRC, a study for the detection of colorectal cancer (CRC) at the Western Colorectal Cancer Consortium Conference in Portland, Oregon. The study's focus was to enroll subjects that reflected the demographics of the intended use population for a colorectal cancer screening test: average-risk adults between the ages of 45 and 85 across urban and rural communities in the United States. The company offered options of virtual enrollment, electronic consenting and mobile phlebotomy that enabled home blood draws for participants who were not geographically close or able to visit a hospital or other study site. Analysis of results demonstrate enrollment strategies were effective in recruiting an intended-use population. Freenome is in the final stages of development of its blood-based screening test for colorectal cancer. The test uses Freenome's multiomics platform, which combines tumor and non-tumor signals with machine learning to detect cancer in the earliest, most treatable stages using a standard blood draw. The test is intended to offer an accessible and convenient option for CRC screening.

CLINICAL STUDY

#ml

#software

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

American Cancer Society Releases New Colorectal Cancer Statistics; Rapid Shifts to More Advanced Disease and Younger People

Colorectal cancer is swiftly shifting to more advanced disease and younger individuals according to Colorectal Cancer Statistics 2023, a new report on cancer facts and trends by the American Cancer Society (ACS). Researchers showed the proportion of individuals in the United States diagnosed with advanced-stage colorectal cancer (CRC) increased from 52% in the mid-2000s to 60% in 2019.

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

Worldwide Companion Diagnostics Industry to 2028: Increase in Incidence of Medication Reactions and Increasing Prevalence of Cancer Cases and Fatalities Drives Growth

The global companion diagnostics market is projected to progress with a CAGR of 12.84% during the forecast period 2022-2028. The prominent factors fueling the global market's growth include a surge in medication reaction incidence, increasing cancer cases, and the growing use of precision medicines.

#cdx

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023 TOP STORY

Careology and The Royal Marsden collaborate to improve mental health support for people living and dealing with cancer

Funded by The Royal Marsden Cancer Charity, the Careology app will provide access to a wide range of content specifically tailored for the needs of young people. It will include information on the topics identified by young people as most important to them including managing symptoms, fatigue, body image, food and nutrition and mental health support, specifically around dealing with anxiety.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

New Clinical AI Solutions Enable Early Disease Detection and Proactive Care for Patients with Lower GI Disorders, Diabetes and Prediabetes

Lucem Health™ today announced the availability of its new early disease detection solutions, Lucem Health Reveal. Lucem Health Reveal leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease. Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization. The Lucem Health Reveal solutions developed in partnership with Medial EarlySign use clinical data already in patient charts to identify patients who appear to be at a higher risk for Diabetes or Lower GI disorders including colorectal cancer detection.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

Rakuten Medical to Host Research & Development Day on Investigational Alluminox™ Platform

Rakuten Medical, Inc., a global biotechnology company developing precision, cell-targeting therapies based on its proprietary photoimmunotherapy technology Alluminox™ platform, today announced that it will host a Research & Development Day on Thursday, March 16, 2023 from 12:30 p.m. – 2:00 p.m. ET / 9:30 a.m. – 11:00 a.m. PT. This virtually held event will showcase the possibilities of Rakuten Medical's oncology technology and its lead investigational compound ASP-1929 for investors.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 01,2023

National Survey Shows People Need More Education on Colon Cancer Screening

March is National Colorectal Cancer Awareness Month and a new survey conducted by MedStar Health shows people need more education when it comes to colon cancer screening. The survey of 1000 American adults found: 59% are concerned about getting colorectal cancer, and just 22% identified the correct age for a first colonoscopy.

View Analyst & Ambassador Comments
Go to original news
Jan 26,2023

FOSANIS EXPANDS TO ASSIST CANCER PATIENTS IN GREAT BRITAIN

Mika, an AI-driven Digital Therapeutics (DTx) platform suitable for all types of cancer, is now available in British app stores. Mika provides cancer patients with easy-to-understand and contextually relevant disease education as well as evidence-based behavioural techniques to improve their self-management, self-efficacy and quality of life.

PRODUCT

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 28,2023 TOP STORY

Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology. Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. Pfizer also has access to Tempus’ broad range of capabilities that support therapeutic R&D to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#cdx

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY